Xeris Pharmaceuticals Inc (XERS) Stock Price, Quote & News

Company Profile

Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the...

Industry: Biotechnology

Sector: Healthcare

Phone: 844 445 5704

Website: www.xerispharma.com

Address:

1375 West Fulton Street, Suite 1300, Chicago, United States

BuyThisOne Oct. 4 at 11:42 PM

$XERS Not a big chart person but if we just started the handle on a 5 year cup and handle we may see a drop the next few weeks until earnings and then pop to $11 or so if earnings are good. My chart from going big at $1.07 is looking spectacular no matter what happens short term so zero fear here. Really excited to see that 5 year chart in early 2028 from those days of buying at $1 here.

0 · Reply

NewEra8 Oct. 4 at 11:01 PM

$XERS I am struggling with injury at the moment but we’re not giving up, open up your trading app, go to XERS and then press 1Y…….171%…..i don’t need to talk a lot, I am counting a shit ton of money

1 · Reply

gimoozaabi Oct. 4 at 10:07 PM

$XERS note to self Company will turn profitable in 2025

0 · Reply

LiquidThetaLEAPS Oct. 4 at 6:41 PM

LiquidTheta® LEAPS LIVE Actionable Alert Asset: $XERS Current Share Price: $8.20 Contracts: $XERS April 17, 2026 $10 Calls Scale in: $0.88- $1.07 Scale out: $1.36-$1.76 Can Easily Capture: 60% ROI Blended DTE: 196 Days | Join Elites here: https://liquidtheta.com/options

0 · Reply

PJACOB01 Oct. 4 at 3:49 PM

$XERS I was bored so I asked this question and got surprised:

0 · Reply

Finwizard61 Oct. 4 at 3:34 PM

$XERS Folks please don’t forget what mgmt said in Aug 2025..👇👇👇👇👇 Total guidance raised to $280-$290MM! This is hell of a positive outlook. Revenue growth expected to be higher in 2025 compared to 2024 by at least 49%! I believe that both outlooks fairly conservative. I expect a 5-10% beat on those outlook based on a super q4 Recorlev revenue no. Also 40 new hires were given stock options last week. Hiring ramped up to increase revenue for Recorlev. 2026 will be a SUPER SUPER year for Xeris. Market cap of $1.2B is below 4 times next years Revenue. Should be close to 6-7 x 2026 projected Revenue.. Any guesses for 2026 Revenue- my guess at least $360-380mm: Projected Market Cap s/b 6 x Revenue = $2.3B.. approx double the current stock price.. this is all without considering progress on Levo.. Bottom line - I reiterated a strong buy and raise 12 month price target to $18-19 by end of 2026!

0 · Reply

PJACOB01 Oct. 3 at 8:28 PM

$XERS It seems like the Shorts are still putting up a fight.

0 · Reply

dave2ta Oct. 3 at 7:05 PM

$XERS Because It's Friday, I'm sharing a Song with all of my Friends... It's titled "Forgotten Word", and it shares my take on all the "new" technology that's available to keep our children trapped in their rooms, while they should be out playing with their friends. What do you think about it??? https://soundcloud.com/daveevanssolo/forgotten-word?si=f3ba802193c1457ea36791336ec97f89&utm_source=clipboard&utm_medium=text&utm_campaign=social_sharing

2 · Reply

KTdad Oct. 3 at 6:54 PM

$XERS not happy to just close one gap today?!

0 · Reply

RunsWithDogs Oct. 3 at 6:12 PM

$XERS Nice! Gap closed. Hopefully we gain the rest of the day!

0 · Reply

Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 5, 2025, 10:03 AM EDT - 4 weeks ago

Xeris In Recorlev-Fuelled Growth: Why I Choose To Buy

Aug 25, 2025, 7:00 AM EDT - 5 weeks ago

Xeris Announces Orange Book Listing of U.S. Patent for Recorlev®

Aug 7, 2025, 7:38 PM EDT - 2 months ago

Xeris Biopharma Holdings, Inc. (XERS) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 7:00 AM EDT - 2 months ago

Xeris Biopharma Reports Record Financial Results for the Second Quarter 2025 and Raises Full Year Revenue Guidance

Jul 31, 2025, 7:30 AM EDT - 2 months ago

Xeris Biopharma to Report Second Quarter 2025 Financial Results on August 7, 2025

Jun 18, 2025, 10:17 AM EDT - 3 months ago

Xeris Biopharma: Great Numbers, Great Technologies, And Suitable For Long-Term Investing

Jun 3, 2025, 7:30 AM EDT - 4 months ago

Xeris Unveils Strategy for Long-Term Growth and Value Creation at 2025 Analyst & Investor Day

May 20, 2025, 7:30 AM EDT - 4 months ago

Xeris Announces Details for Analyst & Investor Day

May 8, 2025, 2:15 PM EDT - 5 months ago

Xeris Biopharma Holdings, Inc. (XERS) Q1 2025 Earnings Call Transcript

May 8, 2025, 7:00 AM EDT - 5 months ago

Xeris Biopharma Reports Record First Quarter 2025 Financial Results

May 7, 2025, 11:51 AM EDT - 5 months ago

Xeris Biopharma Holdings: Looking For More Growth In Q1 Earnings

May 1, 2025, 7:00 AM EDT - 5 months ago

Xeris Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025

Mar 28, 2025, 8:00 AM EDT - 6 months ago

Xeris Announces Changes to Its Board of Directors

Mar 17, 2025, 8:00 AM EDT - 7 months ago

Xeris Announces Approval of Supplemental New Drug Application (sNDA) of Gvoke VialDx™ (glucagon) for Use as a Diagnostic Aid

Mar 6, 2025, 10:52 AM EST - 7 months ago

Xeris Biopharma Holdings, Inc. (XERS) Q4 2024 Earnings Call Transcript

Mar 6, 2025, 7:00 AM EST - 7 months ago

Xeris Biopharma Delivers Record Fourth Quarter and Full-Year 2024 Results; and Announces 2025 Guidance

Feb 27, 2025, 7:00 AM EST - 7 months ago

Xeris Biopharma to Report Fourth Quarter and Full-Year 2024 Financial Results on March 6, 2025

Feb 24, 2025, 8:00 AM EST - 7 months ago

Xeris Appoints Anh Nguyen, MD, MBA as Chief Medical Officer

Feb 5, 2025, 8:00 AM EST - 8 months ago

Xeris to Participate in Upcoming Investor Conferences

Jan 21, 2025, 9:00 AM EST - 9 months ago

The American Diabetes Association and Xeris Pharmaceuticals Announce National Collaboration to Provide Life-Saving Hypoglycemia Education and Awareness

Jan 10, 2025, 7:00 AM EST - 9 months ago

Xeris Expects to Exceed Full-Year 2024 Financial Guidance

Jan 6, 2025, 4:15 PM EST - 9 months ago

Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Nov 26, 2024, 7:00 AM EST - 11 months ago

Xeris to Participate in Piper Sandler 36th Annual Healthcare Conference

Nov 8, 2024, 11:50 AM EST - 11 months ago

Xeris Biopharma Holdings, Inc. (XERS) Q3 2024 Earnings Call Transcript

Nov 8, 2024, 7:00 AM EST - 11 months ago

Xeris Biopharma Reports Third Quarter 2024 Financial Results

Oct 31, 2024, 8:00 AM EDT - 1 year ago

Xeris Biopharma to Report Third Quarter 2024 Financial Results on November 8, 2024

Oct 25, 2024, 12:50 PM EDT - 1 year ago

Xeris Biopharma Holdings: Promising Pipeline And Strategic Partnerships Make It Attractive

Oct 11, 2024, 2:00 PM EDT - 1 year ago

Undercovered Dozen: KinderCare Learning, Xeris Biopharma, Generac, Philips +

GNRC KLC PHG

Oct 9, 2024, 11:33 AM EDT - 1 year ago

Xeris Biopharma: Time For A Reassessment

Aug 8, 2024, 11:56 AM EDT - 1 year ago

Xeris Biopharma Holdings, Inc. (XERS) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 7:00 AM EDT - 1 year ago

Xeris Biopharma Reports Second Quarter 2024 Financial Results

Jul 25, 2024, 7:00 AM EDT - 1 year ago

Xeris Biopharma to Report Second Quarter 2024 Financial Results on August 8, 2024

Jul 8, 2024, 7:00 AM EDT - 1 year ago

Xeris Biopharma Announces CEO Succession Plan

Jun 3, 2024, 7:00 AM EDT - 1 year ago

Xeris Presents New Post Hoc Analysis on Effects of Levoketoconazole (Recorlev®) in Cushing's Syndrome Patients at ENDO 2024

May 30, 2024, 7:30 AM EDT - 1 year ago

Xeris Biopharma Announces Positive Topline Phase 2 Clinical Data of Its Investigational XeriSol™-Formulated Once-Weekly Subcutaneous (SC) Levothyroxine (XP-8121)

May 30, 2024, 7:00 AM EDT - 1 year ago

Xeris to Participate in the Jefferies Global Healthcare Conference

May 9, 2024, 12:49 PM EDT - 1 year ago

Xeris Biopharma Holdings, Inc. (XERS) Q1 2024 Earnings Call Transcript

May 9, 2024, 7:00 AM EDT - 1 year ago

Xeris Biopharma Reports First Quarter 2024 Financial Results and Recent Events

May 6, 2024, 7:00 AM EDT - 1 year ago

Xeris Enters Into an Exclusive Worldwide Collaboration and License Agreement with Beta Bionics

May 2, 2024, 7:00 AM EDT - 1 year ago

Xeris Biopharma to Report First Quarter 2024 Financial Results on May 9, 2024

Apr 3, 2024, 4:05 PM EDT - 1 year ago

Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Apr 2, 2024, 7:00 AM EDT - 1 year ago

Xeris Biopharma to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Mar 30, 2024, 1:28 AM EDT - 1 year ago

Xeris Biopharma: Checking-In On One Of My 'Top Ideas'

Mar 6, 2024, 12:43 PM EST - 1 year ago

Xeris Biopharma (XERS) Q4 2023 Earnings Call Transcript

Mar 6, 2024, 7:02 AM EST - 1 year ago

Xeris Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Events

Mar 6, 2024, 7:00 AM EST - 1 year ago

Xeris Refinances Its $150M Senior Secured Term Loan Facility With Hayfin Capital

Feb 28, 2024, 7:00 AM EST - 1 year ago

Xeris Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on March 6, 2024

Feb 5, 2024, 7:00 AM EST - 1 year ago

Xeris to Present at the Oppenheimer 34th Annual Healthcare Life Science Conference

Jan 10, 2024, 8:00 AM EST - 1 year ago

Xeris Biopharma Enters Into an Exclusive Worldwide License Agreement for Xeriject® Formulation of Teprotumumab

BuyThisOne Oct. 4 at 11:42 PM

0 · Reply

NewEra8 Oct. 4 at 11:01 PM

1 · Reply

gimoozaabi Oct. 4 at 10:07 PM

$XERS note to self Company will turn profitable in 2025

0 · Reply

LiquidThetaLEAPS Oct. 4 at 6:41 PM

0 · Reply

PJACOB01 Oct. 4 at 3:49 PM

$XERS I was bored so I asked this question and got surprised:

0 · Reply

Finwizard61 Oct. 4 at 3:34 PM

0 · Reply

PJACOB01 Oct. 3 at 8:28 PM

$XERS It seems like the Shorts are still putting up a fight.

0 · Reply

dave2ta Oct. 3 at 7:05 PM

2 · Reply

KTdad Oct. 3 at 6:54 PM

$XERS not happy to just close one gap today?!

0 · Reply

RunsWithDogs Oct. 3 at 6:12 PM

$XERS Nice! Gap closed. Hopefully we gain the rest of the day!

0 · Reply

pascallambrecht Oct. 3 at 5:43 PM

$XERS the way go to 9/10 up

0 · Reply

RunsWithDogs Oct. 3 at 5:18 PM

$XERS If I had my choice of dropping to fill the 8.31 gap vs staying put at 8.37 over the weekend, I'd much rather close the gap. The best would be filling it now and then up on power hour, of course. Only a few weeks from an awesome Q3 earnings report. Cheers and have a great weekend everyone!

1 · Reply

SparkyReturns Oct. 3 at 3:10 PM

$XERS Holy cow, this thing really is going to $40 some day, and not too far off once they hit profitability and monetize XP-8121.

1 · Reply

Finwizard61 Oct. 3 at 3:09 PM

$XERS According to Market beat Xeris short position is much much higher.. more like over 14,500,000 shares!! Wow imagine if they have to cover over $10 the stock can jump to $15..inevitably they will have to cover.. Wow, I totally underestimated the short positions! Hugely bullish for us long retail investors. I am buying as much as i can as quickly as possible because one day we can see $1-2 move up!!

0 · Reply

Northwoodspeculator Oct. 3 at 2:49 PM

$XERS new high

0 · Reply

JAAAAAY123 Oct. 3 at 2:43 PM

Nice going $XERS, for a DEAD company.

1 · Reply

Finwizard61 Oct. 3 at 1:54 PM

$XERS Hold the line, “millions of shares that are shorted have to start to cover!” Company is in the right trajectory.. easy double figures on the horizon.. to our retail investor friends DONT SELL a SINGLE share.. Time to give the shorties maximum pain .. for the years of pain they inflicted on us!

0 · Reply

Struin Oct. 3 at 1:43 PM

$XERS Look at MLTX from 62 to 7, now rebound!

2 · Reply

Finwizard61 Oct. 3 at 1:37 PM

$XERS Now trading at 52 week high - $8.37 x $8.39!!

0 · Reply

Finwizard61 Oct. 3 at 1:36 PM

$XERS Picked up another 300 shares..

0 · Reply

Ithaca2018 Oct. 3 at 1:04 PM

$XERS Princess! We should see a new 52W High today;-)

2 · Reply

xersdave Oct. 3 at 11:06 AM

$XERS Dear John, $20 BO + $12 CVR on LEVO. Get er done!

2 · Reply

Market Cap	1.34B
Revenue (ttm)	203.07M
Net Income (ttm)	-54.84M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-27.01%
Debt to Equity Ratio	-11.33

Volume	1,953,000
Avg Vol	2,553,552
Day's Range	N/A - N/A
Shares Out	161.48M
Stochastic %K	92%
Beta	0.39
Analysts	Strong Sell
Price Target	$9.00